Xoma up on broadly positive data, but questions remain

Analysts want to know of the drug's long-term potential and said the data were still too early

Xoma says it has made good on its proof-of-concept test for its experimental drug XOMA-358 in postbariatric surgery hyperinsulinism (PBS) and congenital hyperinsulinism (CHI) as its shares jumped 7.7% after hours.

In all, the company presented updated data from 13 patients (up 2 from former data posts) treated with PBS and 14 with CHI (up from 7 previously reported) in phase 2a trials, and the biotech said that in the latter group, in acute studies, “have met their objectives of establishing initial safety and 358 proof-of-concept aged 12 and up across several dosing levels.”

It said it is also “nearing” a multi-dose study in children with CHI aged 2 and up, which is slated to be done in the U.K.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Meanwhile, the PBS study has completed dosing in the single-dose cohorts, and has also met its objectives, the biotech said, adding that a a multi-dose study has also been started.

The drug is a fully human negative allosteric modulating insulin receptor antibody derived from the XMet platform.

Analysts at Jefferies took a measured view, saying: “Given the limited data we believe it is still too early to build XOMA-358 into Xoma’s valuation. Two critical features that need to be determined are the durability of the treatment (and long-term treatment potential) and whether XOMA-358 raises the glucose levels in younger patients (patients between 2-12). The latter is important as some CHI patients tend to 'outgrow' their CHI around the ages of 10-15yrs.”

A lot is riding on this med as back in 2015, the company was hit by a catastrophic failure of a key development program that knocked Xoma into penny stock territory. The company reported that its Servier-partnered drug for Behcet's disease flunked a late-stage study.

The biotech, which reportedly laid off staff in a reorganization, was left with a share price that had shrunk 80%, but later signed a life-extending deal with Novartis that involved out-licensing a cancer med to its long-term partner. 

Read more on

Suggested Articles

The FDA warned healthcare providers about cybersecurity vulnerabilities within certain clinical information systems made by GE Healthcare.

Weeks after receiving FDA approval for its in-office eardrum tube device, Tusker Medical has been picked up by Smith & Nephew for an undisclosed sum.

What a difference a day makes in biotech.